Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.36 |
| ▸ | PTGIR | P43119 | 2/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.30 |
| ▸ | PTGFR | P43088 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22263537 | 1.00 | PDE4D (0.37) | PDE4DPTGER1PTGER3PTGIRPTGDR | |
| SCHEMBL28457532 | 1.00 | PDE4D (0.37) | PDE4DPTGER1PTGER3PTGIRPTGDR | |
| SCHEMBL22278903 | 0.92 | PDE4D (0.39) | PDE4DPTGER1PTGER3PTGIRPTGDR | |
| SCHEMBL22278867 | 0.92 | PDE4D (0.39) | PDE4DPTGER1PTGER3PTGIRPTGDR | |
| SCHEMBL20815455 | 0.84 | PDE4D (0.44) | PDE4DPTGER1PTGER3PTGIRPTGDR | |
| SCHEMBL20815457 | 0.84 | PDE4D (0.44) | PDE4DPTGER1PTGER3PTGIRPTGDR | |
| SCHEMBL20991777 | 0.80 | PTGER1 (0.32) | PTGER1PTGER3PTGIRPTGDRPTGER2 | |
| SCHEMBL20991861 | 0.80 | PDE4D (0.40) | PDE4DPTGER1PTGER3PTGIRPTGDR | |
| SCHEMBL20815491 | 0.78 | PTGIR (0.43) | PDE4DPTGER1PTGER3PTGIRPTGDR | |
| SCHEMBL20815490 | 0.78 | PTGIR (0.43) | PDE4DPTGER1PTGER3PTGIRPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3705472-B1 | METHOD FOR PRODUCING PROSTAGLANDIN DERIVATIVE | AGC INC (JP) | 2023-06-21 | — | — | EP | disclosed |
| US-11377413-B2 | Method for producing prostaglandin derivative | AGC Inc. (JP) | 2022-07-05 | — | — | US | disclosed |
| US-20200239397-A1 | METHOD FOR PRODUCING PROSTAGLANDIN DERIVATIVE | AGC Inc. (JP) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377413-B2 | Method for producing prostaglandin derivative | PTGS1, PTGIS, PTGER1 | PDE4D 340/4885PTGER1 3/4885PTGER3 10/4885 |
| US-20200239397-A1 | METHOD FOR PRODUCING PROSTAGLANDIN DERIVATIVE | PTGS1, PTGIS, PTGER1 | PDE4D 340/4885PTGER1 3/4885PTGER3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.